证券代码：002030 证券简称：达安基因 公告编号：2025-050 3、本次股东会以现场投票与网络投票相结合的方式召开。 一、会议召开和出席情况 （一）会议召开情况 1、会议召开时间： 广州达安基因股份有限公司 2025 年第三次临时股东会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会未出现否决议案的情形。 2、本次股东会未涉及变更前次股东会决议。 （1）现场会议召开时间：2025 年 9 月 15 日下午 14:30 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的时间为 2025 年 9 月 15 日上午 9:15—9:25，9:30—11:30 和下午 13:00—15:00；通过深圳 证券交易所互联网投票系统投票的时间为 2025 年 9 月 15 日上午 9:15 至 2025 年 9 月 15 日下午 15:00 期间的任意时间。 2、会议召开地点：广州市高新技术开发区科学城香山路 19 号公司一楼讲学 厅 3、会议召开方式：现场投票与网络投票相结合的方式 4、会议召集人：公司董事会 5、会议主 ...

1. 经公司 2024 年第三次临时股东会审议通过的《公司章程》； 2. 公司 2025 年 8 月 30 日刊登于《证券时报》《上海证券报》《经济参 考报》、巨潮资讯网（www.cninfo.com.cn）及深圳证券交易所网站的 《广州达安基因股份有限公司第九届董事会第一次会议决议公告》； 3. 公司于 2025 年 8 月 30 日刊登于《证券时报》《上海证券报》《经济 参考报》、巨潮资讯网（www.cninfo.com.cn）及深圳证券交易所网站 的《广州达安基因股份有限公司第八届监事会第七次会议决议公告》； 4. 公司 2025 年 8 月 30 日刊登于《证券时报》《上海证券报》《经济参 考报》、巨潮资讯网（www.cninfo.com.cn）及深圳证券交易所网站的 《广州达安基因股份有限公司关于召开 2025 年第三次临时股东会通知 的公告》（以下简称《股东会通知》）； 5. 本次股东会股权登记日（2025 年 9 月 9 日）的股东名册； 6. 出席现场会议的股东的到会登记记录及凭证资料； 北京市金杜（广州）律师事务所 关于广州达安基因股份有限公司 2025 年第三次临时股东会的法律意见书 致： ...

Group 1 - The company, Da An Gene, announced that it has recently obtained a medical device registration certificate issued by the National Medical Products Administration [2]

Core Viewpoint - The company, DaAn Gene, has obtained a medical device registration certificate from the National Medical Products Administration for an HIV-1 DNA testing kit, indicating a significant advancement in its product offerings and potential market impact [1]. Company Summary - The medical device is named "HIV-1 DNA Test Kit (PCR-Fluorescent Probe Method)" and has been assigned the registration number 20253401805 [1]. - The certificate is valid from the date of approval until September 4, 2030, which suggests a long-term regulatory compliance for the product [1]. - The intended use of the product is for the qualitative detection of HIV-1 DNA in human whole blood samples, specifically targeting the M group [1]. Industry Summary - The approval of this testing kit aligns with the growing demand for reliable diagnostic tools in the healthcare sector, particularly for infectious diseases like HIV [1]. - The introduction of advanced testing methods may enhance the overall capabilities of the industry in managing and diagnosing HIV infections [1].

Group 1 - The company, DaAn Gene (002030.SZ), has recently obtained a medical device registration certificate from the National Medical Products Administration [1] - The registered product is an HIV-1 DNA test kit (PCR fluorescent probe method), with the registration number: Guo Xie Zhu Zheng 20253401805 [1] - The certificate is valid from the date of approval until September 4, 2030, and the product is intended for in vitro qualitative detection of HIV-1 DNA in human whole blood samples [1]

Core Viewpoint - The company, Da An Gene, has recently obtained a medical device registration certificate from the National Medical Products Administration for an HIV-1 DNA testing kit, indicating a significant advancement in its product offerings [1]. Group 1 - The medical device registration certificate is specifically for the Human Immunodeficiency Virus Type 1 (HIV-1) DNA testing kit using PCR fluorescent probe method [1]. - The registration certificate number is 国械注准20253401805, and it is valid from the date of approval until September 4, 2030 [1]. - The expected use of this product is for the qualitative detection of HIV-1 DNA in human blood samples, specifically targeting the M group [1].

Core Viewpoint - The company, DaAn Gene, has recently obtained a medical device registration certificate from the National Medical Products Administration for an HIV-1 DNA test kit, indicating a significant advancement in its product offerings in the field of medical diagnostics [1] Group 1 - The medical device is named the Human Immunodeficiency Virus Type 1 (HIV-1) DNA Test Kit (PCR Fluorescent Probe Method) [1] - The expected use of this product is for the in vitro qualitative detection of HIV-1 DNA in human whole blood samples, specifically targeting the M group [1]

广州达安基因股份有限公司 证券代码：002030 证券简称：达安基因 公告编号：2025-049 医疗器械名称：人类免疫缺陷病毒 1 型（HIV-1）DNA 检测试剂盒（PCR- 荧光探针法），注册证编号：国械注准 20253401805。有效期自批准之日起至 2030 年 9 月 4 日。预期用途：本产品用于体外定性检测人全血样本中的人类免疫缺陷 病毒 1 型脱氧核糖核酸（HIV-1 DNA）（仅 M 组）。 上述医疗器械注册证的取得丰富了公司的产品组合，拓宽了公司产品的应用 领域。目前，上述产品尚处于市场开发阶段，市场需求存在不确定性，请广大投 资者注意投资风险。 特此公告。 广州达安基因股份有限公司 关于取得一个医疗器械注册证的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，广州达安基因股份有限公司（以下简称"公司"）取得国家药品监督管 理局颁发的医疗器械注册证一个，具体为： 董 事 会 2025 年 9 月 8 日 ...

Core Viewpoint - The company emphasizes the importance of enhancing its own value while acknowledging that its stock price is influenced by various factors including operational performance, macroeconomic conditions, and industry environment [1] Group 1 - The company is committed to managing its market value based on market and operational conditions [1] - The company plans to implement a series of measures aimed at reducing losses and increasing profits, although the effectiveness of these measures will require validation from the market [1] - Investors are encouraged to monitor the company's regular reports and announcements for specific product and financial information [1]

Core Viewpoint - The company, Da'an Gene, reported that as of August 29, 2025, the total number of shareholders is approximately 146,000 [1] Summary by Categories - **Company Information** - Da'an Gene's total number of shareholders is projected to be around 146,000 by the specified date [1]